Ferroptosis's Master Switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with <i>in vitro</i> experiments validation.

ABSTRACT:

Introduction

Glutathione peroxidase 4 (GPX4) is a key enzyme in ferroptosis. Gaining insight into GPX4's mechanisms and biological roles could offer valuable therapeutic insights for cancer treatment.

Methods

By integrating multi-omics data from The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression Project (GTEx), cBioPortal, the Human Protein Atlas (HPA), UALCAN, Xiaotao platform and et al., we applied systematic bioinformatics approaches to evaluate the expression, prognostic significance, mutation profiles, DNA methylation and tumor immune microenvironment (TIME) infiltration of GPX4 across diverse cancer types. Furthermore, the role of GPX4 in cell proliferation was experimentally validated.

Results

GPX4 was upregulated in several cancer types. Its potent

SUBMITTER: Li X 

PROVIDER: S-EPMC12545133 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature